Search Results
Search for other papers by Walid Zeyghami in
Google Scholar
PubMed
Search for other papers by Marie-Louise Uhre Hansen in
Google Scholar
PubMed
Search for other papers by Kathrine Kronberg Jakobsen in
Google Scholar
PubMed
Search for other papers by Christian Groenhøj in
Google Scholar
PubMed
Department of Clinical Medicine, Faculty of Health and Clinical Sciences, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Ulla Feldt-Rasmussen in
Google Scholar
PubMed
Department of Clinical Medicine, Faculty of Health and Clinical Sciences, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Christian von Buchwald in
Google Scholar
PubMed
Search for other papers by Christoffer Holst Hahn in
Google Scholar
PubMed
in cancer patients is due to an increase in the release of circulating tumor DNA (ctDNA) ( Payne et al. 2018 ). The challenge is to discriminate between ctDNA and DNA from normal healthy tissue. One way is to utilize somatic mutations found in
Search for other papers by Kristina Warton in
Google Scholar
PubMed
Garvan Institute of Medical Research, Chris O'Brien Lifehouse, The Kinghorn Cancer Centre and St Vincent's Clinical School, 370 Victoria Street, Darlinghurst, Sydeny, New South Wales, Australia
Search for other papers by Kate L Mahon in
Google Scholar
PubMed
Search for other papers by Goli Samimi in
Google Scholar
PubMed
; and repeated biopsies from a patient are not practicable. Circulating tumor DNA (ctDNA) containing the same molecular aberrations as the solid tumor is detectable in the bloodstream of many cancer patients ( Ignatiadis & Dawson 2014 ), and sampling it
Search for other papers by Simon Garinet in
Google Scholar
PubMed
Search for other papers by Juliette Nectoux in
Google Scholar
PubMed
Search for other papers by Mario Neou in
Google Scholar
PubMed
INSERM UMR745, Biological and Pharmaceutical Sciences University, Université Paris Descartes, Sorbonne Paris Cité, Paris, France
Search for other papers by Eric Pasmant in
Google Scholar
PubMed
Department of Medical Oncology, Hôpital Cochin, Assistance Publique – Hôpitaux de Paris, Paris, France
Search for other papers by Anne Jouinot in
Google Scholar
PubMed
Search for other papers by Mathilde Sibony in
Google Scholar
PubMed
Search for other papers by Lucie Orhant in
Google Scholar
PubMed
Search for other papers by Juliana Pipoli da Fonseca in
Google Scholar
PubMed
Search for other papers by Karine Perlemoine in
Google Scholar
PubMed
Search for other papers by Léopoldine Bricaire in
Google Scholar
PubMed
Department of Endocrinology, Cochin Hospital, Assistance Publique – Hôpitaux de Paris, Paris, France
Search for other papers by Lionel Groussin in
Google Scholar
PubMed
Search for other papers by Olivier Soubrane in
Google Scholar
PubMed
Search for other papers by Bertrand Dousset in
Google Scholar
PubMed
Department of Endocrinology, Cochin Hospital, Assistance Publique – Hôpitaux de Paris, Paris, France
Search for other papers by Rossella Libe in
Google Scholar
PubMed
Search for other papers by Franck Letourneur in
Google Scholar
PubMed
Department of Endocrinology, Cochin Hospital, Assistance Publique – Hôpitaux de Paris, Paris, France
Reference Center for Rare Adrenal Diseases, Reference Center for Rare Adrenal Cancer Network COMETE, Hôpital Cochin, AssistancePublique – Hôpitaux de Paris, Paris, France
Search for other papers by Jérome Bertherat in
Google Scholar
PubMed
Department of Endocrinology, Cochin Hospital, Assistance Publique – Hôpitaux de Paris, Paris, France
Reference Center for Rare Adrenal Diseases, Reference Center for Rare Adrenal Cancer Network COMETE, Hôpital Cochin, AssistancePublique – Hôpitaux de Paris, Paris, France
Search for other papers by Guillaume Assié in
Google Scholar
PubMed
surrogate biomarkers for detecting circulating tumor DNA (ctDNA) in blood. This ctDNA corresponds to fragments of DNA released directly by tumor cells into the blood stream among the circulating cell-free DNA (ccfDNA). Discrimination of ctDNA from ccfDNA of
Search for other papers by Masaki Shiota in
Google Scholar
PubMed
Search for other papers by Shusuke Akamatsu in
Google Scholar
PubMed
Search for other papers by Shigehiro Tsukahara in
Google Scholar
PubMed
Search for other papers by Shohei Nagakawa in
Google Scholar
PubMed
Search for other papers by Takashi Matsumoto in
Google Scholar
PubMed
Search for other papers by Masatoshi Eto in
Google Scholar
PubMed
et al. 2009 ). Among them, several mutations in the LBD were frequently and reproducibly detected in tissues and circulating tumor DNA (ctDNA) from patients with prostate cancer by NGS ( Table 2 ). In a study using prostate cancer tissues, T878A (2
Graduate Program in Microbiology, Immunology, and Cancer Biology, University of Minnesota, Minneapolis, Minnesota, USA
Search for other papers by Mark Daniel in
Google Scholar
PubMed
Search for other papers by Todd P Knutson in
Google Scholar
PubMed
Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin, USA
Search for other papers by Jamie M Sperger in
Google Scholar
PubMed
Search for other papers by Yingming Li in
Google Scholar
PubMed
Search for other papers by Anupama Singh in
Google Scholar
PubMed
Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin, USA
Search for other papers by Charlotte N Stahlfeld in
Google Scholar
PubMed
Search for other papers by Courtney Passow in
Google Scholar
PubMed
Search for other papers by Benjamin Auch in
Google Scholar
PubMed
Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin, USA
Search for other papers by Joshua M Lang in
Google Scholar
PubMed
Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota, USA
Department of Urology, University of Minnesota, Minneapolis, Minnesota, USA
Search for other papers by Scott M Dehm in
Google Scholar
PubMed
resistance to the second-generation hormonal therapies abiraterone and enzalutamide ( Antonarakis et al. 2014 , 2015 , Scher et al. 2016 , 2018 ). Another common liquid biopsy approach is the detection of circulating tumor DNA (ctDNA) shed from
Gastroenterology and Technologies for Health, Centre de Cancérologie de Lyon, INSERM U1052-CNRS UMR5286, Centre Léon Bérard, Lyon, France
Search for other papers by Laura Gerard in
Google Scholar
PubMed
Search for other papers by Céline Patte in
Google Scholar
PubMed
Search for other papers by Laurence Chardon in
Google Scholar
PubMed
Service Central d’Anatomie et Cytologie Pathologiques, Hospices Civils de Lyon, Hôpital Edouard Herriot, Lyon, France
Search for other papers by Valérie Hervieu in
Google Scholar
PubMed
Search for other papers by Léa Payen in
Google Scholar
PubMed
Search for other papers by Marion Allio in
Google Scholar
PubMed
Search for other papers by Claire Marx in
Google Scholar
PubMed
Search for other papers by Hugo Clermidy in
Google Scholar
PubMed
Search for other papers by Alice Durand in
Google Scholar
PubMed
Search for other papers by Patrick Mehlen in
Google Scholar
PubMed
Search for other papers by Julien Bollard in
Google Scholar
PubMed
Search for other papers by Gilles Poncet in
Google Scholar
PubMed
Search for other papers by Colette Roche in
Google Scholar
PubMed
Search for other papers by Benjamin Gibert in
Google Scholar
PubMed
Gastroenterology and Technologies for Health, Centre de Cancérologie de Lyon, INSERM U1052-CNRS UMR5286, Centre Léon Bérard, Lyon, France
Search for other papers by Thomas Walter in
Google Scholar
PubMed
. 2021 ). In patients with cancer, the circulating tumour DNA (ctDNA) originates from tumour cells and represents a small fraction of circulating cell-free DNA (cfDNA). It can reflect the tumour mutational burden and is correlated with disease course in
CNRS UMR7275, Valbonne, France
NEOGENEX CNRS International Associated Laboratory, Valbonne, France
Institut de Pharmacologie Moléculaire et Cellulaire, Valbonne, France
Search for other papers by Enzo Lalli in
Google Scholar
PubMed
Search for other papers by Michaela Luconi in
Google Scholar
PubMed
referred to a simple blood draw that can provide material released from the tumor into the bloodstream, such as circulating tumor cells (CTCs), miRNAs, exosomes and cell-free DNA of tumor origin (ctDNA) ( Fig. 2 ). This is a novel and minimally invasive
Search for other papers by Darren Cowzer in
Google Scholar
PubMed
Search for other papers by Ronak H Shah in
Google Scholar
PubMed
Search for other papers by Joanne F Chou in
Google Scholar
PubMed
Search for other papers by Ritika Kundra in
Google Scholar
PubMed
Search for other papers by Sippy Punn in
Google Scholar
PubMed
Search for other papers by Laura Fiedler in
Google Scholar
PubMed
Search for other papers by April DeMore in
Google Scholar
PubMed
Search for other papers by Marinela Capanu in
Google Scholar
PubMed
Department of Pathology and laboratory medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
Search for other papers by Michael F Berger in
Google Scholar
PubMed
Weill Medical College of Cornell University, New York, New York, USA
Search for other papers by Diane Reidy-Lagunes in
Google Scholar
PubMed
Weill Medical College of Cornell University, New York, New York, USA
Search for other papers by Nitya Raj in
Google Scholar
PubMed
targeted intervention ( Diehl et al. 2008 , Diaz & Bardelli 2014 ). Currently, data in panNENs relating to circulating tumor (ct)DNA detection and quantification from cfDNA, or the use of cfDNA for tumor molecular profiling, are limited. Prior efforts
St Vincent’s Clinical School, UNSW Sydney, Sydney, New South Wales, Australia
Search for other papers by H H Milioli in
Google Scholar
PubMed
Search for other papers by S Alexandrou in
Google Scholar
PubMed
St Vincent’s Clinical School, UNSW Sydney, Sydney, New South Wales, Australia
Search for other papers by E Lim in
Google Scholar
PubMed
St Vincent’s Clinical School, UNSW Sydney, Sydney, New South Wales, Australia
Search for other papers by C E Caldon in
Google Scholar
PubMed
(Cristofanilli et al. 2016) ~8.9 month follow up PFS: 9.5 months vs 4.6 months (HR: 0.46; 95% CI: 0.36–0.59; two-sided P < 0.0001) ctDNA analysis of PIK3CA mutation at baseline (Turner et al. 2018) OS: 34.9 months vs 28 months (HR: 0
Search for other papers by Thomas Ho Lai Yau in
Google Scholar
PubMed
Search for other papers by Kwok-Leung Cheung in
Google Scholar
PubMed
– • Stomatitis (8% vs 1%) • Anaemia (6% vs <1%) • Hyperglycaemia (4% vs <1%) • Pneumonitis (3% vs 0%) – Fulvestrant + buparlisib vs fulvestrant + placebo (Baselga et al . 2016) 6.9 vs 5.0 PIK3CA mutant ctDNA (7.0 vs 3.2) 12 vs 8 PIK3CA mutant ctDNA